SEC Form 4 · accession 0001209191-15-081520
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Margaret G McGlynn
Director
Period of report
Nov 18, 2015
Accepted (ET)
Nov 20, 2015 · 4:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 18, 2015 | M | 12,500 | $57.27 | A | 13,588 | D | |
| Common StockF2,F3 | Nov 18, 2015 | S | 12,500 | $130.15 | D | 1,088 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $57.27 | Nov 18, 2015 | M | 12,500 | D | — | May 11, 2021 | Common Stock | 12,500 | 0 | D |
Explanation of responses
- F1Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $130.15 (range $130.00 to $130.55).
- F3Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Fully vested.